Norway: Teva Norway AS v. Astrazeneca Ab, District Court of Olso, 13-189803TVI-OTIR/04, 27 June 2014

Kluwer Patent Blog
February 19, 2015

Please refer to this post as: , ‘Norway: Teva Norway AS v. Astrazeneca Ab, District Court of Olso, 13-189803TVI-OTIR/04, 27 June 2014’, Kluwer Patent Blog, February 19 2015, http://patentblog.kluweriplaw.com/2015/02/19/norway-teva-norway-as-v-astrazeneca-ab-district-court-of-olso-13-189803tvi-otir04-27-june-2014/


The Oslo District Court held that the expired Norwegian patent 306452 (“452 Patent”) was invalid due to lack of inventive step, which implied that its supplementary protection certificate SPC014 was invalid as well. The court also found the 176 Patent invalid.

A full summary of this case has been published on Kluwer IP Law.